GSK’s Jemperli (dostarlimab) won accelerated FDA approval for advanced rectal cancer patients with a specific genetic signature, according to the label expansion announcement. The approval adds to Jemperli’s earlier use in endometrial cancer and places the PD-1 blocker into a broader colorectal footprint as competitors expand similarly across the disease site. The update underscores how molecular patient-selection strategies are shaping checkpoint inhibitor approvals in GI oncology. While the announcement confirms the regulatory action, it does not provide the underlying efficacy or safety figures in the release text. For biotech teams, the move raises the stakes for comparability of study designs, endpoints, and biomarker definitions across rectal-cancer trials. It also increases competitive pressure on next-line regimens that rely on immunotherapy sequencing after initial therapy.